ClinicalTrialsFinder
RecruitingPhase 2NCT06302491

A Study of Safety and Efficiency of AND017 in Patients With β-thalassemia

A Study of Safety and Efficiency of AND017 in Patients With Transfusion Dependent and Non-transfusion Dependent β-thalassemia

Sponsor

Kind Pharmaceuticals LLC

Enrollment

64 participants

Start Date

May 27, 2024

Study Type

INTERVENTIONAL

Conditions

Thalassemia

Summary

This is a phase II, randomized, double-blinded, placebo-controlled study to treat patients with transfusion-dependent and non-transfusion dependent β -thalassemia with AND017 and optimal supportive care, including blood transfusion and iron removal, based on the clinician's judgment and practice.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called AND017 Placebo and a drug called AND017 capsules for people with thalassemia. The study is currently recruiting participants at 5 locations. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAND017 capsules

Administer AND017 capsules once per day (QD)

DRUGAND017 Placebo

Administer AND017 matching placebo capsules once per day (QD)

Locations(5)

Nanfang Hospital Southern Medical University

Guangzhou, Guangdong, China

Maoming People's Hospital

Maoming, Guangdong, China

Liuzhou People's Hospital

Liuzhou, Guangxi, China

Guangxi Medical University No.1 Affiliated Hospital

Nanning, Guangxi, China

Hainan General Hospital

Haikou, Hainan, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06302491

Related Trials

A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

NCT06609226105 locations

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

NCT057364196 locations

A Real-World Study to Evaluate Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle East

NCT072159752 locations

Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease

NCT054775636 locations

Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling

NCT063133981 location